Biopharma companies secured $102.15 billion in funding in 2024, a 44% increase from $70.97 billion in the full-year 2023 and significantly higher than the $60.81 billion raised in 2022. December financings reached $4.69 billion, marking an increase from $3.6 billion in November.

After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that targets TDP-43, a protein directly linked to amyotrophic lateral sclerosis (ALS) pathology.

Balt Group SAS recently secured €355 million (US$365 million) in funding to refinance its debt, invest in research and accelerate its growth. The French-based provider of interventional neuroradiology devices is looking to speed up the expansion of its global footprint, especially in the U.S.

Med-tech companies raised $25.36 billion in financings in 2024, marking a 43% increase from $17.68 billion in 2023. December saw a significant rise, with $1.72 billion raised, compared to $919.99 million in November.

Zhongzhi Pharmaceutical Holdings Ltd. made a $3 million investment in a series A financing round of stem cell therapy developer Gabaeron Inc. Dec. 21, expected to help propel Gabaeron’s preclinical Alzheimer’s disease (AD) candidate into phase I testing.

Despite a sometimes-turbulent stock market and over 18,000 job losses, 2024 closed with signs of recovery, marked by growth in both financings and deals, setting an optimistic tone for 2025.